Increasing evidence strongly suggests that bevacizumab compound impacts the immunological signature of cancer patients and normalizes tumor vasculature. This study aims to investigate the correlation between the clinical response to bevacizumab-based chemotherapy and the improvement of immune fitness of multi-treated ovarian cancer patients. Peripheral blood mononuclear cells (PBMCs) of 20 consecutive recurrent ovarian cancer patients retrospectively selected to have received bevacizumab or non-bevacizumab-based chemotherapy (Bev group and Ctrl group, respectively) were analyzed. CD4, CD8, and regulatory T cell (Treg) subsets were monitored at the beginning (T0) and after three and six cycles of treatment, together with IL10 production. A lower activated and resting Treg subset was found in the Bev group compared with the Ctrl group until the third therapy cycle, suggesting a reduced immunosuppressive signature. Indeed, clinically responding patients in the Bev group showed a high percentage of nonsuppressive Treg and a significant lower IL10 production compared with non-responding patients in the Bev group after three cycles. Furthermore, clinically responding patients showed a discrete population of effector T cell at T0 independent of the therapeutic regimen. This subset was maintained throughout the therapy in only the Bev group. This study evidences that bevacizumab could affect the clinical response of cancer patients, reducing the percentage of Treg and sustaining the circulation of the effector T cells. Results also provide a first rationale regarding the positive immunologic synergism of combining bevacizumab with immunotherapy in multi-treated ovarian cancer patients.

Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector t cell subsets / Napoletano, Chiara; Ruscito, Ilary; Bellati, Filippo; Zizzari, ILARIA GRAZIA; RAHIMI KOSHKAKI, Hassan; Gasparri, MARIA LUISA; Antonilli, Morena; BENEDETTI PANICI, Pierluigi; Rughetti, Aurelia; Nuti, Marianna. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 8:3(2019), pp. 1-12. [10.3390/jcm8030380]

Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector t cell subsets

Chiara Napoletano
Co-primo
;
Ilary Ruscito
Co-primo
;
Filippo Bellati
Secondo
;
Ilaria Grazia Zizzari;Hassan Rahimi;Maria Luisa Gasparri;Morena Antonilli;Pierluigi Benedetti Panici;Aurelia Rughetti
Penultimo
;
Marianna Nuti
Ultimo
2019

Abstract

Increasing evidence strongly suggests that bevacizumab compound impacts the immunological signature of cancer patients and normalizes tumor vasculature. This study aims to investigate the correlation between the clinical response to bevacizumab-based chemotherapy and the improvement of immune fitness of multi-treated ovarian cancer patients. Peripheral blood mononuclear cells (PBMCs) of 20 consecutive recurrent ovarian cancer patients retrospectively selected to have received bevacizumab or non-bevacizumab-based chemotherapy (Bev group and Ctrl group, respectively) were analyzed. CD4, CD8, and regulatory T cell (Treg) subsets were monitored at the beginning (T0) and after three and six cycles of treatment, together with IL10 production. A lower activated and resting Treg subset was found in the Bev group compared with the Ctrl group until the third therapy cycle, suggesting a reduced immunosuppressive signature. Indeed, clinically responding patients in the Bev group showed a high percentage of nonsuppressive Treg and a significant lower IL10 production compared with non-responding patients in the Bev group after three cycles. Furthermore, clinically responding patients showed a discrete population of effector T cell at T0 independent of the therapeutic regimen. This subset was maintained throughout the therapy in only the Bev group. This study evidences that bevacizumab could affect the clinical response of cancer patients, reducing the percentage of Treg and sustaining the circulation of the effector T cells. Results also provide a first rationale regarding the positive immunologic synergism of combining bevacizumab with immunotherapy in multi-treated ovarian cancer patients.
bevacizumab; ovarian cancer; effector t cells
01 Pubblicazione su rivista::01a Articolo in rivista
Bevacizumab-based chemotherapy triggers immunological effects in responding multi-treated recurrent ovarian cancer patients by favoring the recruitment of effector t cell subsets / Napoletano, Chiara; Ruscito, Ilary; Bellati, Filippo; Zizzari, ILARIA GRAZIA; RAHIMI KOSHKAKI, Hassan; Gasparri, MARIA LUISA; Antonilli, Morena; BENEDETTI PANICI, Pierluigi; Rughetti, Aurelia; Nuti, Marianna. - In: JOURNAL OF CLINICAL MEDICINE. - ISSN 2077-0383. - 8:3(2019), pp. 1-12. [10.3390/jcm8030380]
File allegati a questo prodotto
File Dimensione Formato  
Napoletano_Bevacizumab-based-chemotherapy_2019.pdf

accesso aperto

Note: La natura "Open access" della "policy" e la corrispondente licenza "CC-BY/4.0 Attribution License" sono riportate in calce alla pagina 12 del "full text" della versione editoriale allegata.
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 758.58 kB
Formato Adobe PDF
758.58 kB Adobe PDF Visualizza/Apri PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1249040
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 19
social impact